The medical technology company is transitioning leadership to focus on its next phase of growth and commercial traction for its obstructive sleep apnea therapy in the US market.
Key takeaways:
- Nyxoah has launched a search for a new US-based CEO to succeed Olivier Taelman, who has led the company for seven years.
- The leadership transition is designed to accelerate the US commercial launch of Genio, a hypoglossal neurostimulation therapy for OSA.
- Taelman will remain fully engaged in daily operations during the transition period to support the onboarding of the future chief executive officer.
Nyxoah has announced the commencement of a leadership transition process to further accelerate the company’s US commercial traction.
Following seven years leading Nyxoah, Olivier Taelman, together with the board of directors, decided to transition leadership to a US-based CEO as the company enters its next phase of US-driven growth and value creation. The board has formally launched a search process to appoint a new leader who will guide Nyxoah from within a critical market for the company’s future growth.
Taelman will remain fully engaged during the transition period, continuing to lead the company’s daily operations and supporting a smooth onboarding for the future chief executive officer.
“Leading Nyxoah over the past seven years has been one of the most rewarding journeys of my professional career,” says Olivier Taelman, Nyxoah CEO, in a release. He notes that during his tenure, the team grew the company from an early-stage clinical entity into a global commercial medical technology platform with FDA approval, successful IPOs, and a promising early commercial launch of Genio in the United States.
“We appreciate Olivier Taelman’s outstanding contributions,” says Robert Taub, chairman, in a release. “The combination of strengthened financial resources, accelerating US commercial momentum, and a US-focused leadership structure will position Nyxoah well for its next phase of growth in the rapidly expanding OSA market.”
Nyxoah’s lead solution is the Genio system, a leadless and battery-free hypoglossal neurostimulation therapy for obstructive sleep apnea. The system received its European CE Mark in 2019 and was FDA-approved in August 2025 as a prescription-only device.
